Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Crestor Campaign Makes FDA Complain; "Clearly The Best" Given A Rest

This article was originally published in The Pink Sheet Daily

Executive Summary

An FDA "untitled" letter takes issue with AstraZeneca's presentation of comparative claims to other statins in an ad campaign that states Crestor is "clearly the best." This is the second ad division letter sent to AstraZeneca for Crestor promotions. AstraZeneca says the FDA-cited campaign concluded at the end of 2004.

You may also be interested in...



Crestor's New Ad: Dr. Seuss Is Out, "Direct" Presentation Of Benefit/Risk Is In

AstraZeneca launches TV commericals that touts Crestor's 52% LDL reduction efficacy. The ad notes the Adult Treatment Panel III July 2004 recommendation for more aggressive therapy. The risk information is presented by an on-screen spokesman instead of a voiceover.

Crestor's New Ad: Dr. Seuss Is Out, "Direct" Presentation Of Benefit/Risk Is In

AstraZeneca launches TV commericals that touts Crestor's 52% LDL reduction efficacy. The ad notes the Adult Treatment Panel III July 2004 recommendation for more aggressive therapy. The risk information is presented by an on-screen spokesman instead of a voiceover.

Aggrenox Journal Ad Improperly Suggests Superiority To Plavix, FDA Says

The paper referenced in the ad is "a historically controlled trial that is inadequate to support a superiority claim," the FDA ad division letter states. The agency also cites the Aggrenox ad for omitting risk information.

Related Content

Topics

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel